iBio Inc announced the release of its updated corporate presentation on June 3, 2024, showcasing its transformation into a machine learning-enabled antibody discovery company. The presentation highlights their proprietary AI-driven technology stack for developing first-in-class and best-in-class therapeutic antibodies.The company's platform integrates multiple technologies including Epitope Steering, StableHu antibody optimization, EngageTx bispecific antibodies, and ShieldTx masking technology. The pipeline includes six preclinical programs targeting hard-to-drug molecules in immuno-oncology and cardio-metabolic diseases, with lead asset IBIO-101 showing promising early development data.iBio has established multiple strategic partnerships, including collaborations with Eli Lilly, NIH, and AstralBio, validating their AI-driven approach. The company's business model focuses on both proprietary pipeline development and platform licensing opportunities in specific disease areas.

iBio Inc announced the release of its updated corporate presentation on June 3, 2024, showcasing its transformation into a machine learning-enabled antibody discovery company. The presentation highlights their proprietary AI-driven technology stack for developing first-in-class and best-in-class therapeutic antibodies.The company's platform integrates multiple technologies including Epitope Steering, StableHu antibody optimization, EngageTx bispecific antibodies, and ShieldTx masking technology. The pipeline includes six preclinical programs targeting hard-to-drug molecules in immuno-oncology and cardio-metabolic diseases, with lead asset IBIO-101 showing promising early development data.iBio has established multiple strategic partnerships, including collaborations with Eli Lilly, NIH, and AstralBio, validating their AI-driven approach. The company's business model focuses on both proprietary pipeline development and platform licensing opportunities in specific disease areas.